Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 246

1.

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study.

Cazzaniga ME, Pinotti G, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Fiorentini G, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Marchetti P, Melegari E, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Saracchini S, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Clivio L, Torri V; VICTOR Study Group.

Breast. 2019 Aug 22;48:7-16. doi: 10.1016/j.breast.2019.07.006. [Epub ahead of print]

PMID:
31470257
2.

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study.

Di Cosimo S, La Verde N, Moretti A, Cazzaniga ME, Generali D, Bianchi GV, Mariani L, Torri V, Crippa F, Paolini B, Scaperrotta G, De Santis MC, Di Nicola M, Apolone G, Gulino A, Tripodo C, Colombo MP, Folli S, de Braud F.

PLoS One. 2019 Aug 7;14(8):e0220644. doi: 10.1371/journal.pone.0220644. eCollection 2019.

3.

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.

Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, Vici P.

Int J Cancer. 2019 Jul 22. doi: 10.1002/ijc.32583. [Epub ahead of print]

PMID:
31330065
4.

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

Cazzaniga ME, Biganzoli L, Cortesi L, De Placido S, Donadio M, Fabi A, Ferro A, Generali D, Lorusso V, Milani A, Montagna E, Munzone E, Orlando L, Pizzuti L, Simoncini E, Zamagni C, Pappagallo GL; “Metronomic Chemotherapy in Advanced Breast Cancer” Study Group.

Onco Targets Ther. 2019 Apr 23;12:2989-2997. doi: 10.2147/OTT.S189163. eCollection 2019.

5.

Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success.

Cazzaniga ME, Danesi R, Girmenia C, Invernizzi P, Elvevi A, Uguccioni M; NetworkER+.

Breast Cancer Res Treat. 2019 Aug;176(3):483-494. doi: 10.1007/s10549-019-05261-5. Epub 2019 May 7. Review.

6.

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.

Cazzaniga M, Verusio C, Ciccarese M, Fumagalli A, Sartori D, Valerio MR, Airoldi M, Moretti G, Ficorella C, Arcangeli V, Diodati L, Zambelli A, Febbraro A, Generali D, Pistelli M, Garrone O, Musolino A, Vici P, Maur M, Mentuccia L, La Verde N, Bianchi G, Artale S, Blasi L, Piezzo M, Atzori F, Turletti A, Benedetto C, Cursano MC, Fabi A, Gebbia V, Schirone A, Palumbo R, Ferzi A, Frassoldati A, Scavelli C, Clivio L, Torri V.

Oncotarget. 2018 Nov 30;9(94):36720-36721. doi: 10.18632/oncotarget.26431. eCollection 2018 Nov 30.

7.

Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project.

Cazzaniga ME, Munzone E, Bocci G, Afonso N, Gomez P, Langkjer S, Petru E, Pivot X, Sánchez Rovira P, Wysocki P, Torri V.

Adv Ther. 2019 Feb;36(2):381-406. doi: 10.1007/s12325-018-0844-4. Epub 2018 Dec 18.

PMID:
30565179
8.

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.

Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, Mentuccia L, Fabbri A, Barba M, Sanguineti G, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Airoldi F, Orlandi A, Moscetti L, Sergi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L, De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamagni C, Rubino D, Cortesi E, Magri V, Pomati G, Scagnoli S, Capomolla E, Kayal R, Scinto AF, Corsi D, Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carbognin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficorella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, Vici P.

J Cell Physiol. 2019 Jun;234(6):7708-7717. doi: 10.1002/jcp.27832. Epub 2018 Dec 10.

PMID:
30536609
9.

Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project.

Cazzaniga ME, Ciruelos E, Fabi A, Garcia-Saenz J, Lindman H, Mavroudis D, Schem C, Steger G, Timotheadou E, Zaman K, Torri V; MACBETH Group.

Cancer Chemother Pharmacol. 2019 Feb;83(2):301-318. doi: 10.1007/s00280-018-3717-2. Epub 2018 Nov 20.

PMID:
30460489
10.

Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.

Leo S, Arnoldi E, Repetto L, Coccorullo Z, Cinieri S, Fedele P, Cazzaniga M, Lorusso V, Latorre A, Campanella G, Ciccarese M, Accettura C, Pisconti S, Rinaldi A, Brunetti C, Raffaele M, Coltelli L, Spazzapan S, Fratino L, Petrucelli L, Biganzoli L.

Oncologist. 2019 Jun;24(6):e232-e240. doi: 10.1634/theoncologist.2017-0676. Epub 2018 Nov 9.

PMID:
30413667
11.

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.

Cazzaniga M, Verusio C, Ciccarese M, Fumagalli A, Sartori D, Valerio MR, Airoldi M, Moretti G, Ficorella C, Arcangeli V, Diodati L, Zambelli A, Febbraro A, Generali D, Pistelli M, Garrone O, Musolino A, Vici P, Maur M, Mentuccia L, La Verde N, Bianchi G, Artale S, Blasi L, Piezzo M, Atzori F, Turletti A, Benedetto C, Cursano MC, Fabi A, Gebbia V, Schirone A, Palumbo R, Ferzi A, Frassoldati A, Scavelli C, Clivio L, Torri On Behalf Of The Eva Study Group V.

Oncotarget. 2018 Oct 2;9(77):34639-34640. doi: 10.18632/oncotarget.26213. eCollection 2018 Oct 2.

12.

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.

Cazzaniga M, Verusio C, Ciccarese M, Fumagalli A, Sartori D, Valerio MR, Ancona C, Airoldi M, Moretti G, Ficorella C, Arcangeli V, Diodati L, Zambelli A, Febbraro A, Generali D, Pistelli M, Garrone O, Musolino A, Vici P, Maur M, Mentuccia L, La Verde N, Bianchi G, Artale S, Blasi L, Piezzo M, Atzori F, Turletti A, Benedetto C, Cursano MC, Fabi A, Gebbia V, Schirone A, Palumbo R, Ferzi A, Frassoldati A, Scavelli C, Clivio L, Torri On Behalf Of The Eva Study Group V.

Oncotarget. 2018 Aug 7;9(61):31877-31887. doi: 10.18632/oncotarget.25874. eCollection 2018 Aug 7. Erratum in: Oncotarget. 2018 Oct 2;9(77):34639-34640. Valerio, Maria Rosario [added]. Oncotarget. 2018 Nov 30;9(94):36720-36721.

13.

Assistive powered exoskeleton for complete spinal cord injury: correlations between walking ability and exoskeleton control.

Guanziroli E, Cazzaniga M, Colombo L, Basilico S, Legnani G, Molteni F.

Eur J Phys Rehabil Med. 2019 Apr;55(2):209-216. doi: 10.23736/S1973-9087.18.05308-X. Epub 2018 Aug 27.

14.

Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine?

Cazzaniga M, Bonanni B.

Anticancer Res. 2018 Aug;38(8):4393-4402. doi: 10.21873/anticanres.12741. Review.

PMID:
30061203
15.

β-Diketonate ancillary ligands in heteroleptic iridium complexes: a balance between synthetic advantages and photophysical troubles.

Penconi M, Cazzaniga M, Kesarkar S, Baldoli C, Mussini PR, Ceresoli D, Bossi A.

Photochem Photobiol Sci. 2018 Sep 12;17(9):1169-1178. doi: 10.1039/c8pp00052b.

PMID:
30047955
16.

Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study.

Cerrito MG, De Giorgi M, Pelizzoni D, Bonomo SM, Digiacomo N, Scagliotti A, Bugarin C, Gaipa G, Grassilli E, Lavitrano M, Giovannoni R, Bidoli P, Cazzaniga ME.

Oncotarget. 2018 Jun 8;9(44):27448-27459. doi: 10.18632/oncotarget.25422. eCollection 2018 Jun 8.

17.

Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?

Cazzaniga ME, Munzone E, Montagna E, Pappagallo G.

Expert Rev Anticancer Ther. 2018 Aug;18(8):805-814. doi: 10.1080/14737140.2018.1489244. Epub 2018 Jul 4.

PMID:
29902087
18.

π-π-Induced aggregation and single-crystal fluorescence anisotropy of 5,6,10b-tri-aza-acephenanthrylene.

Ostrowska K, Ceresoli D, Stadnicka K, Gryl M, Cazzaniga M, Soave R, Musielak B, Witek ŁJ, Goszczycki P, Grolik J, Turek AM.

IUCrJ. 2018 Apr 18;5(Pt 3):335-347. doi: 10.1107/S2052252518001987. eCollection 2018 May 1.

19.

Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve.

Alberti P, Rossi E, Argyriou AA, Kalofonos HP, Briani C, Cacciavillani M, Campagnolo M, Bruna J, Velasco R, Cazzaniga ME, Cortinovis D, Valsecchi MG, Cavaletti G.

Support Care Cancer. 2018 Sep;26(9):3143-3151. doi: 10.1007/s00520-018-4170-9. Epub 2018 Mar 29.

PMID:
29594485
20.

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?

Cazzaniga ME, Cortesi L, Ferzi A, Scaltriti L, Cicchiello F, Ciccarese M, Torre SD, Villa F, Giordano M, Verusio C, Nicolini M, Gambaro AR, Zanlorenzi L, Biraghi E, Casini E, Legramandi L, Rulli E.

Int J Breast Cancer. 2017;2017:1683060. doi: 10.1155/2017/1683060. Epub 2017 Dec 3. Review.

21.

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.

Cazzaniga ME, Airoldi M, Arcangeli V, Artale S, Atzori F, Ballerio A, Bianchi GV, Blasi L, Campidoglio S, Ciccarese M, Cursano MC, Piezzo M, Fabi A, Ferrari L, Ferzi A, Ficorella C, Frassoldati A, Fumagalli A, Garrone O, Gebbia V, Generali D, La Verde N, Maur M, Michelotti A, Moretti G, Musolino A, Palumbo R, Pistelli M, Porpiglia M, Sartori D, Scavelli C, Schirone A, Turletti A, Valerio MR, Vici P, Zambelli A, Clivio L, Torri V; on behalf of; EVA Study Group.

Breast. 2017 Oct;35:115-121. doi: 10.1016/j.breast.2017.06.043. Epub 2017 Jul 13.

PMID:
28711793
22.

Upper limit to the ultimate achievable emission wavelength in near-IR emitting cyclometalated iridium complexes.

Penconi M, Cazzaniga M, Kesarkar S, Mussini PR, Ceresoli D, Bossi A.

Photochem Photobiol Sci. 2017 Aug 9;16(8):1220-1229. doi: 10.1039/c7pp00119c.

PMID:
28677718
23.

Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.

Generali D, Montemurro F, Bordonaro R, Mafodda A, Romito S, Michelotti A, Piovano P, Ionta MT, Bighin C, Sartori D, Frassoldati A, Cazzaniga ME, Riccardi F, Testore F, Vici P, Barone CA, Schirone A, Piacentini F, Nolè F, Molino A, Latini L, Simoncini EL, Roila F, Cognetti F, Nuzzo F, Foglietta J, Minisini AM, Goffredo F, Portera G, Ascione G, Mariani G.

Oncologist. 2017 Jun;22(6):648-654. doi: 10.1634/theoncologist.2016-0461. Epub 2017 Apr 21.

24.

A Presurgical Study of Lecithin Formulation of Green Tea Extract in Women with Early Breast Cancer.

Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D, Cazzaniga M, Aristarco V, Macis D, Mora S, Caldarella P, Pagani G, Pruneri G, Riva A, Petrangolini G, Morazzoni P, DeCensi A, Bonanni B.

Cancer Prev Res (Phila). 2017 Jun;10(6):363-370. doi: 10.1158/1940-6207.CAPR-16-0298. Epub 2017 Apr 11.

25.

Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials.

Bernardo A, Palumbo R, Pedersini R, Rota Caremoli E, Gambaro AR, Ferzi A, Riva F, Grasso D, Danova M, Tarenzi E, Torri V, Cazzaniga ME.

Clin Breast Cancer. 2017 Oct;17(6):433-440. doi: 10.1016/j.clbc.2017.03.004. Epub 2017 Mar 9.

PMID:
28366406
26.

Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.

Ciccarese M, Fabi A, Moscetti L, Cazzaniga ME, Petrucelli L, Forcignanò R, Lupo LI, De Matteis E, Chiuri VE, Cairo G, Febbraro A, Giordano G, Giampaglia M, Bilancia D, La Verde N, Maiello E, Morritti M, Giotta F, Lorusso V, Latorre A, Scavelli C, Romito S, Cusmai A, Palmiotti G, Surico G.

Breast Cancer Res Treat. 2017 Jun;163(3):587-594. doi: 10.1007/s10549-017-4213-9. Epub 2017 Mar 28.

PMID:
28353061
27.

Metronomic chemotherapy for advanced breast cancer patients.

Cazzaniga ME, Dionisio MR, Riva F.

Cancer Lett. 2017 Aug 1;400:252-258. doi: 10.1016/j.canlet.2016.12.019. Epub 2016 Dec 23. Review.

PMID:
28017894
28.

In reply to Kadri Altundag.

Cazzaniga ME.

Breast Cancer Res Treat. 2017 Jan;161(2):387. doi: 10.1007/s10549-016-4056-9. Epub 2016 Nov 21. No abstract available.

PMID:
27873134
29.

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.

Cazzaniga ME, Cortesi L, Ferzi A, Scaltriti L, Cicchiello F, Ciccarese M, Della Torre S, Villa F, Giordano M, Verusio C, Nicolini M, Gambaro AR, Zanlorenzi L, Biraghi E, Legramandi L, Rulli E; VICTOR Study Group.

Breast Cancer Res Treat. 2016 Dec;160(3):501-509. doi: 10.1007/s10549-016-4009-3. Epub 2016 Oct 17.

30.

Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study.

Cazzaniga ME, Torri V, Riva F, Porcu L, Cicchiello F, Capici S, Cortinovis D, Digiacomo N, Bidoli P.

Tumori. 2017 Jan 21;103(1):e4-e8. doi: 10.5301/tj.5000543.

PMID:
27647223
31.

Urgent pulmonary lobectomy for blunt chest trauma: report of three cases without mortality.

Chiarelli M, Gerosa M, Guttadauro A, Gabrielli F, Vertemati G, Cazzaniga M, Fumagalli L, De Simone M, Cioffi U.

J Thorac Dis. 2016 Jul;8(7):1825-9. doi: 10.21037/jtd.2016.06.10.

32.

Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.

Guerrieri-Gonzaga A, Sestak I, Lazzeroni M, Serrano D, Rotmensz N, Cazzaniga M, Varricchio C, Pruneri G, Leonardi MC, Orecchia R, Galimberti V, Bonanni B, DeCensi A.

Int J Cancer. 2016 Nov 1;139(9):2127-34. doi: 10.1002/ijc.30254. Epub 2016 Jul 19.

33.

Pharmacoprevention for hereditary breast and ovarian cancer.

Cazzaniga M, Bonanni B.

Minerva Ginecol. 2016 Oct;68(5):517-35. Epub 2016 Feb 29. Review.

PMID:
26928419
34.

Near-IR Emitting Iridium(III) Complexes with Heteroaromatic β-Diketonate Ancillary Ligands for Efficient Solution-Processed OLEDs: Structure-Property Correlations.

Kesarkar S, Mróz W, Penconi M, Pasini M, Destri S, Cazzaniga M, Ceresoli D, Mussini PR, Baldoli C, Giovanella U, Bossi A.

Angew Chem Int Ed Engl. 2016 Feb 18;55(8):2714-8. doi: 10.1002/anie.201509798. Epub 2016 Jan 25.

PMID:
26804423
35.

Breast Cancer Metabolism and Mitochondrial Activity: The Possibility of Chemoprevention with Metformin.

Cazzaniga M, Bonanni B.

Biomed Res Int. 2015;2015:972193. doi: 10.1155/2015/972193. Epub 2015 Oct 28. Review.

36.

Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.

Cazzaniga ME, Camerini A, Addeo R, Nolè F, Munzone E, Collovà E, Del Conte A, Mencoboni M, Papaldo P, Pasini F, Saracchini S, Bocci G.

Future Oncol. 2016 Feb;12(3):373-87. doi: 10.2217/fon.15.306. Epub 2015 Nov 19. Review.

PMID:
26584409
37.

Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study.

Arpino G, Michelotti A, Truini M, Montemurro F, Russo S, Palumbo R, Zamagni C, Latorre A, Bruzzese D, Riccardi F, De Laurentiis M, Beano A, Biganzoli L, Zaniboni A, Laudadio L, Malagoli M, Bilancia D, Schettini F, Giuliano M, Cazzaniga ME, De Placido S.

J Cancer Res Clin Oncol. 2016 Mar;142(3):669-78. doi: 10.1007/s00432-015-2033-z. Epub 2015 Aug 25.

PMID:
26531187
38.

A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer.

Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D, Cazzaniga M, Aristarco V, Puccio A, Mora S, Caldarella P, Pagani G, Pruneri G, Riva A, Petrangolini G, Morazzoni P, DeCensi A, Bonanni B.

Cancer Prev Res (Phila). 2016 Jan;9(1):89-95. doi: 10.1158/1940-6207.CAPR-15-0123. Epub 2015 Nov 2.

40.

Tumor size, stage and grade alterations of urinary peptidome in RCC.

Chinello C, Cazzaniga M, De Sio G, Smith AJ, Grasso A, Rocco B, Signorini S, Grasso M, Bosari S, Zoppis I, Mauri G, Magni F.

J Transl Med. 2015 Oct 20;13:332. doi: 10.1186/s12967-015-0693-8.

41.

Metformin: risk-benefit profile with a focus on cancer.

Provinciali N, Lazzeroni M, Cazzaniga M, Gorlero F, Dunn BK, DeCensi A.

Expert Opin Drug Saf. 2015 Oct;14(10):1573-85. doi: 10.1517/14740338.2015.1084289. Epub 2015 Sep 11. Review.

PMID:
26359221
42.

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A.

Lancet Oncol. 2015 Oct;16(13):1306-15. doi: 10.1016/S1470-2045(15)00122-9. Epub 2015 Aug 31.

PMID:
26338525
43.

Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial.

DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Lazzeroni M, Vingiani A, Gentilini O, Petrera M, Viale G, Cuzick J, Bonanni B, Pruneri G.

Cancer Prev Res (Phila). 2015 Oct;8(10):888-94. doi: 10.1158/1940-6207.CAPR-15-0048. Epub 2015 Aug 14.

44.

Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations.

Del Mastro L, Cazzaniga M, Solidoro P, Generali D, Bianchi G, Testore F, De Placido S.

Future Oncol. 2015;11(16):2251-4. doi: 10.2217/fon.15.134. No abstract available.

PMID:
26260802
45.

Comparative membrane proteomics: a technical advancement in the search of renal cell carcinoma biomarkers.

Raimondo F, Corbetta S, Savoia A, Chinello C, Cazzaniga M, Rocco F, Bosari S, Grasso M, Bovo G, Magni F, Pitto M.

Mol Biosyst. 2015 Jun;11(6):1708-16. doi: 10.1039/c5mb00020c.

46.

Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.

Terrazzino S, Argyriou AA, Cargnin S, Antonacopoulou AG, Briani C, Bruna J, Velasco R, Alberti P, Campagnolo M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Kalofonos HP, Canonico PL, Genazzani AA, Cavaletti G.

J Peripher Nerv Syst. 2015 Mar;20(1):15-23. doi: 10.1111/jns.12110.

PMID:
25858589
47.

Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.

Briani C, Argyriou AA, Izquierdo C, Velasco R, Campagnolo M, Alberti P, Frigeni B, Cacciavillani M, Bergamo F, Cortinovis D, Cazzaniga M, Bruna J, Cavaletti G, Kalofonos HP.

J Peripher Nerv Syst. 2014 Dec;19(4):299-306. doi: 10.1111/jns.12097.

PMID:
25582667
48.

Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.

Allegrini G, Coltelli L, Orlandi P, Fontana A, Camerini A, Ferro A, Cazzaniga M, Casadei V, Lucchesi S, Bona E, Di Lieto M, Pazzagli I, Villa F, Amoroso D, Scalese M, Arrighi G, Molinaro S, Fioravanti A, Finale C, Triolo R, Di Desidero T, Donati S, Marcucci L, Goletti O, Del Re M, Salvadori B, Ferrarini I, Danesi R, Falcone A, Bocci G.

Pharmacogenomics. 2014 Dec;15(16):1985-99. doi: 10.2217/pgs.14.140.

PMID:
25521357
49.

Intraluminal proteome and peptidome of human urinary extracellular vesicles.

Liu X, Chinello C, Musante L, Cazzaniga M, Tataruch D, Calzaferri G, James Smith A, De Sio G, Magni F, Zou H, Holthofer H.

Proteomics Clin Appl. 2015 Jun;9(5-6):568-73. doi: 10.1002/prca.201400085. Epub 2015 Feb 24.

PMID:
25471207
50.

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.

DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, Serrano D, Schwab M, Hofmann U, Mora S, Aristarco V, Macis D, Bassi F, Luini A, Lazzeroni M, Bonanni B, Pollak MN.

Breast Cancer Res Treat. 2014 Nov;148(1):81-90. doi: 10.1007/s10549-014-3141-1. Epub 2014 Sep 25.

Supplemental Content

Loading ...
Support Center